Does supplementation with leucine-enriched protein alone and in combination with fish-oil-derived n–3 PUFA affect muscle mass, strength, physical performance, and muscle protein synthesis in well-nourished older adults? A randomized, double-blind, placebo-controlled trial
| Autor: | Murphy, Caoileann H, Flanagan, Ellen M, De Vito, Giuseppe, Susta, Davide, Mitchelson, Kathleen A J, de Marco Castro, Elena, Senden, Joan M G, Goessens, Joy P B, Mikłosz, Agnieszka, Chabowski, Adrian, Segurado, Ricardo, Corish, Clare A, McCarthy, Sinead N, Egan, Brendan, van Loon, Luc J C, Roche, Helen M |
|---|---|
| Předmět: |
KIDNEY physiology
THERAPEUTIC use of omega-3 fatty acids MUSCLE protein metabolism BIOMARKERS TRIGLYCERIDES GLOMERULAR filtration rate COMBINATION drug therapy LEAN body mass SARCOPENIA DIETARY supplements RANDOMIZED controlled trials PRE-tests & post-tests COMPARATIVE studies PLACEBOS TREATMENT effectiveness LEUCINE MUSCLE strength BODY movement BLIND experiment ADIPONECTIN STATISTICAL sampling FISH oils OLD age |
| Zdroj: | American Journal of Clinical Nutrition; Jun2021, Vol. 113 Issue 6, p1411-1427, 17p, 2 Diagrams, 6 Charts, 1 Graph |
| Abstrakt: | Background Leucine-enriched protein (LEU-PRO) and long-chain (LC) n –3 (ω–3) PUFAs have each been proposed to improve muscle mass and function in older adults, whereas their combination may be more effective than either alone. Objective The impact of LEU-PRO supplementation alone and combined with LC n –3 PUFAs on appendicular lean mass, strength, physical performance and myofibrillar protein synthesis (MyoPS) was investigated in older adults at risk of sarcopenia. Methods This 24-wk, 3-arm parallel, randomized, double-blind, placebo-controlled trial was conducted in 107 men and women aged ≥65 y with low muscle mass and/or strength. Twice daily, participants consumed a supplement containing either LEU-PRO (3 g leucine, 10 g protein; n = 38), LEU-PRO plus LC n –3 PUFAs (0.8 g EPA, 1.1 g DHA; LEU-PRO+ n –3; n = 38), or an isoenergetic control (CON; n = 31). Appendicular lean mass, handgrip strength, leg strength, physical performance, and circulating metabolic and renal function markers were measured pre-, mid-, and postintervention. Integrated rates of MyoPS were assessed in a subcohort (n = 28). Results Neither LEU-PRO nor LEU-PRO+ n– 3 supplementation affected appendicular lean mass, handgrip strength, knee extension strength, physical performance or MyoPS. However, isometric knee flexion peak torque (treatment effect: −7.1 Nm; 95% CI: −12.5, −1.8 Nm; P < 0.01) was lower postsupplementation in LEU-PRO+ n –3 compared with CON. Serum triacylglycerol and total adiponectin concentrations were lower, and HOMA-IR was higher, in LEU-PRO+ n –3 compared with CON postsupplementation (all P < 0.05). Estimated glomerular filtration rate was higher and cystatin c was lower in LEU-PRO and LEU-PRO+ n –3 postsupplementation compared with CON (all P < 0.05). Conclusions Contrary to our hypothesis, we did not observe a beneficial effect of LEU-PRO supplementation alone or combined with LC n –3 PUFA supplementation on appendicular lean mass, strength, physical performance or MyoPS in older adults at risk of sarcopenia. This trial was registered at clinicaltrials.gov as NCT03429491. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|